Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 36Advanced Solid Tumors 20Carcinoma, Non-Small-Cell Lung 14Myelodysplastic Syndromes 13Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Leukemia, Myelomonocytic, Chronic 9Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Solid Tumor 6Prostatic Neoplasms 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Neoplasm Metastasis 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4

Interventions

Tamoxifen 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Subjects × Injections × 1 year × Clear all
NCT06449027 2025-10-01

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
211 enrolled
Breast

Breast Cancer Subjects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡